Idera to Present at the 14th Annual Needham Healthcare Conference
April 13 2015 - 9:00AM
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today
announced that Vincent Milano, Idera's Chief Executive Officer will
present a corporate update at the 14th Annual Needham Healthcare
Conference on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time at
the Westin Grand Central Hotel in New York City.
A live audio webcast of Idera's presentation will be accessible
in the Investors and Media section of Idera's website at
http://www.iderapharma.com. An archived version will also be
available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage patient focused
biopharmaceutical company developing novel therapeutic approaches
for the treatment of cancer and rare diseases. Idera's proprietary
technology involves creating novel nucleic acid therapeutics.
Idera's immunotherapy approach is based on the modulation of
Toll-like receptors (TLRs). In addition to its TLR modulation
programs, Idera is developing gene silencing oligonucleotides (GSO)
technology that it has created to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about
Idera, visit www.iderapharma.com.
CONTACT: Investor and Media Contact
Robert Doody
Vice President, Investor Relations
and Corporate Communications
484-639-7235
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024